Adverse Events Associated With Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms.

Autoimmune Diseases / drug therapy Humans Interleukin-23 / antagonists & inhibitors
adverse events anti-IL-23 biologics meta-analysis systematic review

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 21 02 2021
accepted: 24 05 2021
entrez: 28 6 2021
pubmed: 29 6 2021
medline: 21 10 2021
Statut: epublish

Résumé

Anti-interleukin (IL)-23 agents are widely used for autoimmune disease treatment; however, the safety and risks of specific symptoms have not been systematically assessed. The aim of this study was to summarize the characteristics and mechanisms of occurrence of five immunological and non-immunological adverse events caused by different anti-IL-23 agents. The Cochrane Library, EMBASE, PubMed, and Web of Science databases were searched for eligible randomized clinical trials published from inception through May 1, 2020. Randomized clinical trials that reported at least one type of adverse event after treatment were included, regardless of sex, age, ethnicity, and diagnosis. Two investigators independently screened and extracted the characteristics of the studies, participants, drugs, and adverse event types. The Cochrane Handbook was used to assess the methodological quality of the included randomized clinical trials. Heterogeneity was assessed using the Forty-eight studies were included in the meta-analysis, comprising 25,624 patients treated with anti-IL-23 agents. Serious immunological or non-immunological adverse events were rare. Anti-IL-12/23-p40 agents appeared to cause adverse events more easily than anti-IL-23-p19 agents. The incidence of cancer did not appear to be related to anti-IL-23 agent treatment, and long-term medication could lead to mental diseases. The prevention of complications should be carefully monitored when administered for over approximately 40 weeks to avoid further adverse reactions, and the incidence of infection was the highest among general immunological adverse events. The application of anti-IL-23 agents induced a series of immunological and non-immunological adverse events, but these agents tend to be well-tolerated with good safety profiles.

Sections du résumé

Background
Anti-interleukin (IL)-23 agents are widely used for autoimmune disease treatment; however, the safety and risks of specific symptoms have not been systematically assessed.
Objectives
The aim of this study was to summarize the characteristics and mechanisms of occurrence of five immunological and non-immunological adverse events caused by different anti-IL-23 agents.
Methods
The Cochrane Library, EMBASE, PubMed, and Web of Science databases were searched for eligible randomized clinical trials published from inception through May 1, 2020. Randomized clinical trials that reported at least one type of adverse event after treatment were included, regardless of sex, age, ethnicity, and diagnosis. Two investigators independently screened and extracted the characteristics of the studies, participants, drugs, and adverse event types. The Cochrane Handbook was used to assess the methodological quality of the included randomized clinical trials. Heterogeneity was assessed using the
Results
Forty-eight studies were included in the meta-analysis, comprising 25,624 patients treated with anti-IL-23 agents. Serious immunological or non-immunological adverse events were rare. Anti-IL-12/23-p40 agents appeared to cause adverse events more easily than anti-IL-23-p19 agents. The incidence of cancer did not appear to be related to anti-IL-23 agent treatment, and long-term medication could lead to mental diseases. The prevention of complications should be carefully monitored when administered for over approximately 40 weeks to avoid further adverse reactions, and the incidence of infection was the highest among general immunological adverse events.
Conclusions
The application of anti-IL-23 agents induced a series of immunological and non-immunological adverse events, but these agents tend to be well-tolerated with good safety profiles.

Identifiants

DOI: 10.3389/fimmu.2021.670398 PMID: 34177909 PMC: PMC8226270
pubmed: 34177909
doi: 10.3389/fimmu.2021.670398
pmc: PMC8226270
doi:

Substances chimiques

Interleukin-23 0

Types de publication

Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

670398

Informations de copyright

Copyright © 2021 Ru, Ding, Luo, Li, Sun, Zhou, Zhou, Kuai, Xing, Liu, Luo, Song, Chen, Li and Li.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Biotechnol. 2015 Sep;33(9):894-5
pubmed: 26348946
N Engl J Med. 2015 Jul 9;373(2):136-44
pubmed: 26154787
J Dermatol. 2019 Aug;46(8):686-694
pubmed: 31237727
N Engl J Med. 2017 Apr 20;376(16):1551-1560
pubmed: 28423301
Lancet. 1999 Nov 27;354(9193):1896-900
pubmed: 10584742
J Am Acad Dermatol. 2017 Mar;76(3):405-417
pubmed: 28057360
Basic Clin Pharmacol Toxicol. 2018 Sep;123(3):294-300
pubmed: 29510001
Lancet. 2018 Jun 2;391(10136):2213-2224
pubmed: 29893222
Br J Dermatol. 2011 Sep;165(3):661-8
pubmed: 21574984
Ann Rheum Dis. 2014 Mar;73(3):492-509
pubmed: 24161836
J Invest Dermatol. 2012 Feb;132(2):304-14
pubmed: 22011907
Br J Dermatol. 2017 Dec;177(6):1552-1561
pubmed: 28600818
Br J Dermatol. 2019 Jul;181(1):88-95
pubmed: 30734266
Br J Dermatol. 2015;172(5):1371-83
pubmed: 25307931
N Engl J Med. 2007 Feb 8;356(6):580-92
pubmed: 17287478
J Am Acad Dermatol. 2015 Oct;73(4):594-603
pubmed: 26259989
Nature. 2006 Jul 27;442(7101):461-5
pubmed: 16688182
Nature. 2015 May 14;521(7551):222-6
pubmed: 25754330
J Immunol. 2008 Nov 1;181(9):5948-55
pubmed: 18941183
Immunity. 2011 Oct 28;35(4):596-610
pubmed: 21982596
N Engl J Med. 2016 Nov 17;375(20):1946-1960
pubmed: 27959607
JAMA Dermatol. 2020 Jun 1;156(6):649-658
pubmed: 32267471
Immunity. 2015 Dec 15;43(6):1040-51
pubmed: 26682981
J Exp Med. 2006 Nov 27;203(12):2577-87
pubmed: 17074928
Circulation. 2005 Aug 16;112(7):1054-62
pubmed: 16103256
J Dermatol. 2018 Sep;45(9):1053-1062
pubmed: 29905383
Lancet. 2013 Aug 31;382(9894):780-9
pubmed: 23769296
Eur J Clin Pharmacol. 2016 Nov;72(11):1303-1310
pubmed: 27515978
JAMA Dermatol. 2019 Oct 1;155(10):1153-1161
pubmed: 31268476
J Dermatol. 2012 Mar;39(3):242-52
pubmed: 21955098
Br J Dermatol. 2020 Mar;182(3):605-617
pubmed: 31218661
J Am Acad Dermatol. 2019 Jan;80(1):70-79.e3
pubmed: 29969700
J Dermatolog Treat. 2020 Mar;31(2):152-159
pubmed: 30887876
Rheumatology (Oxford). 2018 Mar 1;57(3):563-571
pubmed: 29244162
Lancet. 2008 May 17;371(9625):1675-84
pubmed: 18486740
JAMA Dermatol. 2020 Apr 1;156(4):393-400
pubmed: 32049319
Br J Dermatol. 2012 Apr;166(4):861-72
pubmed: 22356258
Lancet. 2008 May 17;371(9625):1665-74
pubmed: 18486739
J Allergy Clin Immunol. 2014 Apr;133(4):1032-40
pubmed: 24679469
Clin Drug Investig. 2013 Apr;33(4):291-301
pubmed: 23512638
Br J Dermatol. 2020 Aug;183(2):265-275
pubmed: 31705526
J Dermatol Sci. 2011 Sep;63(3):154-63
pubmed: 21741220
Br J Dermatol. 2020 Feb;182(2):390-397
pubmed: 31004510
Ann Rheum Dis. 2014 Jun;73(6):990-9
pubmed: 24482301
Trends Immunol. 2006 Jan;27(1):17-23
pubmed: 16290228
J Dermatol. 2019 Sep;46(9):752-758
pubmed: 31342560
J Am Acad Dermatol. 2018 Jan;78(1):81-89.e5
pubmed: 28985956
J Crohns Colitis. 2013 May;7(4):257-62
pubmed: 22819590
J Invest Dermatol. 2020 Jan;140(1):85-93.e2
pubmed: 31326395
J Am Acad Dermatol. 2015 Sep;73(3):400-9
pubmed: 26092291
Br J Dermatol. 2017 Oct;177(4):1014-1023
pubmed: 28542874
Br J Dermatol. 2015 Oct;173(4):930-9
pubmed: 26042589
N Engl J Med. 2019 Sep 26;381(13):1201-1214
pubmed: 31553833
JAMA Dermatol. 2020 Jul 1;156(7):787-794
pubmed: 32432649
Lancet. 2017 Jul 15;390(10091):276-288
pubmed: 28596043
N Engl J Med. 2012 Oct 18;367(16):1519-28
pubmed: 23075178
J Immunol. 2008 Oct 1;181(7):4733-41
pubmed: 18802076
Scand J Rheumatol. 2016 Nov;45(6):456-460
pubmed: 27115843
Br J Dermatol. 2018 Mar;178(3):689-696
pubmed: 29222947
Annu Rev Med. 2016;67:337-53
pubmed: 26565676
Allergy. 2006 Aug;61(8):912-20
pubmed: 16867042
Br J Dermatol. 2020 Jun;182(6):1348-1358
pubmed: 31887225
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1151-1160
pubmed: 31721310
JAMA Dermatol. 2018 Mar 1;154(3):309-316
pubmed: 29417135
Gastroenterology. 2020 Feb;158(3):537-549.e10
pubmed: 31493397
J Am Acad Dermatol. 2017 Mar;76(3):418-431
pubmed: 28057361
Br J Dermatol. 2017 Aug;177(2):419-427
pubmed: 28338223
Arthritis Care Res (Hoboken). 2015 Dec;67(12):1739-49
pubmed: 26097039
J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1535-45
pubmed: 23279003
J Am Acad Dermatol. 2017 Jan;76(1):60-69.e9
pubmed: 27663079
N Engl J Med. 2010 Jan 14;362(2):118-28
pubmed: 20071701

Auteurs

Yi Ru (Y)

Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

Xiaojie Ding (X)

Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

Ying Luo (Y)

Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

Hongjin Li (H)

Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

Xiaoying Sun (X)

Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

Mi Zhou (M)

Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Yaqiong Zhou (Y)

Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

Le Kuai (L)

Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

Meng Xing (M)

Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

Liu Liu (L)

Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

Yue Luo (Y)

Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

Jiankun Song (J)

Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

Jiale Chen (J)

Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

Bin Li (B)

Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.
Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.

Xin Li (X)

Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Maladies du système immunitaire › Maladies auto-immunes › Adverse Events Associated With Anti-IL-23...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Adverse Events Associated With Anti-IL-23...
Recherchemedicale.com › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interleukines › Interleukine-23 › Adverse Events Associated With Anti-IL-23...